Tanya Meade1, Nicholas Manolios2, Steven R Cumming2, Philip G Conaghan3, Patricia Katz4. 1. Western Sydney University and University of Sydney, Sydney, New South Wales, Australia. 2. University of Sydney, Sydney, New South Wales, Australia. 3. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and National Institute for Health Research Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK. 4. University of California, San Francisco.
Abstract
OBJECTIVE: Rheumatoid arthritis (RA) is not commonly associated with central nervous system and brain changes. However, a number of studies have reported high rates of cognitive impairment in adults with RA. The objective of this systematic review was to identify and explore the rates and types of cognitive impairment in RA. METHODS: Multiple databases were searched for articles published between 1994 and 2016, to identify studies that have included: adults with RA; standardized neuropsychological tests; and sufficient information to ascertain the relationship between cognitive impairment and demographic, clinical, and psychological factors. Of 1,980 titles, 75 were retained at the abstract level, 36 at the full-text level, and 15 studies in the final review. These were evaluated using a modified Newcastle-Ottawa Scale, and the findings were synthesized using a narrative approach. RESULTS: Ten of 15 studies compared RA to other clinical groups and/or a control group. Based on summed effect size analyses, individuals with RA significantly underperformed on cognitive function tests compared to the control groups, particularly on verbal function, memory, and attention. Less clear differences were found between RA and other clinical groups. Some demographic (age and education), clinical (disease activity), and psychological (depression) factors were associated with cognitive impairment, but inconsistently so across studies. A number of limitations were identified: small and predominantly female samples, limited cognitive domain inclusion, lack of study details, and management of confounding variables. CONCLUSION: There is evidence of cognitive impairment in adults with RA. Further studies are needed to confirm prevalence rates and examine potential mechanisms.
OBJECTIVE:Rheumatoid arthritis (RA) is not commonly associated with central nervous system and brain changes. However, a number of studies have reported high rates of cognitive impairment in adults with RA. The objective of this systematic review was to identify and explore the rates and types of cognitive impairment in RA. METHODS: Multiple databases were searched for articles published between 1994 and 2016, to identify studies that have included: adults with RA; standardized neuropsychological tests; and sufficient information to ascertain the relationship between cognitive impairment and demographic, clinical, and psychological factors. Of 1,980 titles, 75 were retained at the abstract level, 36 at the full-text level, and 15 studies in the final review. These were evaluated using a modified Newcastle-Ottawa Scale, and the findings were synthesized using a narrative approach. RESULTS: Ten of 15 studies compared RA to other clinical groups and/or a control group. Based on summed effect size analyses, individuals with RA significantly underperformed on cognitive function tests compared to the control groups, particularly on verbal function, memory, and attention. Less clear differences were found between RA and other clinical groups. Some demographic (age and education), clinical (disease activity), and psychological (depression) factors were associated with cognitive impairment, but inconsistently so across studies. A number of limitations were identified: small and predominantly female samples, limited cognitive domain inclusion, lack of study details, and management of confounding variables. CONCLUSION: There is evidence of cognitive impairment in adults with RA. Further studies are needed to confirm prevalence rates and examine potential mechanisms.
Authors: Csaba Oláh; Zsófia Kardos; Mónika Andrejkovics; Enikő Szarka; Katalin Hodosi; Andrea Domján; Mariann Sepsi; Attila Sas; László Kostyál; Katalin Fazekas; Ágnes Flórián; Katalin Lukács; Ágnes Miksi; Zsuzsanna Baráth; György Kerekes; Márta Péntek; Attila Valikovics; László Tamási; Dániel Bereczki; Zoltán Szekanecz Journal: Rheumatol Int Date: 2019-09-25 Impact factor: 2.631
Authors: Maria Vassilaki; Cynthia S Crowson; John M Davis Iii; Stephanie Q Duong; David T Jones; Aivi Nguyen; Michelle M Mielke; Prashanthi Vemuri; Elena Myasoedova Journal: J Alzheimers Dis Date: 2022 Impact factor: 4.160
Authors: Li-Ming Wang; Qi Wu; Ryan A Kirk; Kevin P Horn; Ahmed H Ebada Salem; John M Hoffman; Jeffrey T Yap; Joshua A Sonnen; Rheal A Towner; Fernando A Bozza; Rosana S Rodrigues; Kathryn A Morton Journal: Am J Nucl Med Mol Imaging Date: 2018-04-25
Authors: Laura E Petersen; Talita S A Baptista; Júlia K Molina; Julia G Motta; Aline do Prado; Deise M Piovesan; Tatiana de Nardi; Thiago W Viola; Érica L M Vieira; Antonio L Teixeira; Rodrigo Grassi-Oliveira; Moisés Evandro Bauer Journal: Clin Rheumatol Date: 2018-01-25 Impact factor: 2.980
Authors: Joseph E Henriquez; Anthony P Bach; Karina M Matos-Fernandez; Robert B Crawford; Norbert E Kaminski Journal: J Neuroimmune Pharmacol Date: 2020-03-26 Impact factor: 4.147
Authors: Ruth Ann Marrie; Ronak Patel; Charles N Bernstein; James M Bolton; Lesley A Graff; James J Marriott; Carol A Hitchon; Chase R Figley; Jennifer Kornelsen; John D Fisk Journal: Mult Scler Date: 2020-09-25 Impact factor: 6.312
Authors: Ivet Bayes-Marin; Albert Sanchez-Niubo; Laia Egea-Cortés; Hai Nguyen; Matthew Prina; Daniel Fernández; Josep Maria Haro; Beatriz Olaya Journal: BMJ Open Date: 2020-07-19 Impact factor: 2.692
Authors: James M Gwinnutt; Task Toyoda; Stephen Jeffs; Emma Flanagan; Jacqueline R Chipping; Jack R Dainty; Eneida Mioshi; Michael Hornberger; Alex MacGregor Journal: Rheumatol Adv Pract Date: 2021-06-27